{
  "name" : "dacemirror.sci-hub.se_journal-article_df3a6003c1b077c4c81e1b1af5744d87_shahabi2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Protective and anti-inflammatory effect of selenium nano-particles against bleomycin- induced pulmonary injury in male rats",
    "authors" : [ "Rana Shahabi", "Ali Anissian", "Seyed Ali Javadmoosavi", "Farinaz Nasirinezhad" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "GRAPHICAL ABSTRACT\nARTICLE HISTORY Received 30 June 2018 Revised 14 November 2018 Accepted 2 December 2018\nKEYWORDS Pulmonary injury; bleomycin; selenium nanoparticles; tumor necrosis factor alpha; transforming growth factor-beta1"
    }, {
      "heading" : "Introduction",
      "text" : "Pulmonary fibrosis (PF) is an interstitial lung disease, in which the exact pathologic mechanisms are not fully understood. PF is characterized by progressive scarring of lung tissue, lung inflammation, excessive proliferation of fibroblasts, and deposition of extracellular matrix proteins and destruction of the alveolar structure. These pathologic changes result in a gradual decrease in pulmonary function and eventually a respiratory failure (Ryu et al. 2014). Various cytokines have been discovered, that play an important role in the development of pulmonary fibrosis, such as tumor necrosis factor-a (TNF-a), transforming growth factor-b1\nCONTACT Farinaz Nasirinezhad nasirinezhad.f@iums.ac.ir Physiology Research Center, Department of Physiology, Medical school, Iran University of Medical Sciences, Hemmat Expressway, Tehran 14496-14535, Iran 2019 Informa UK Limited, trading as Taylor & Francis Group\n(TGF-b1), platelet-derived growth factor (PDGF) (Yu et al. 2017). Transforming growth factor-beta1 (TGF-b1) plays a very important role in the proliferation and transformation of lung fibroblasts and deposition of extracellular matrix (Lee et al. 2014). TNF-a is a potent proinflammatory cytokine that stimulates the proliferation of fibroblasts and acts as a major molecule in cellular and molecular interactions regulating the fibrotic process (Wynn 2011, Kandhare et al. 2015).\nOne of the anti-cancer drugs is bleomycin (BLM) which causes lung toxicity and could induce pulmonary fibrosis. BLM is used to create an animal model resembling PF (Arai et al. 2000, Moore and Hogaboam 2008). The pathophysiology of BLM-induced pulmonary damage involves two distinct phases as early and late. The early phase (inflammatory reactions) is characterized by infiltration of inflammatory cells and starts at the first week. The late phase (fibrotic reactions) begins at the second week and is characterized by proliferation of fibroblasts and extracellular matrix deposition (Reinert et al. 2013). Many possible treatments for pulmonary fibrosis have shown disappointing results and controversial (Albera et al. 2009).\nSelenium (Se) is an important micronutrient element, which is important for the prevention of neurodegeneration diseases and cancer (Huang et al. 2012). Also, it has been shown that the deficiency of selenium is associated with an increased risk of chronic inflammatory diseases, such as cardiovascular disease and inflammatory bowel disease (IBD) (Fairweather-Tait et al. 2011). Many studies have shown that Se has anti-inflammatory properties (Duntas 2009, Vieira et al. 2012, Kahya et al. 2015). The limiting factors for using selenium are its bioavailability and toxicity; as it displays a narrow margin between effective and toxic doses (Hilton et al. 1980). Elemental selenium nanoparticles (SeNPs) have received a lot of attention due to new features like high surface area, high surface activity, high absorption capacity, high catalytic potential, and lower toxicity (Zhang et al. 2008). Several studies reported that SeNPs have anti-inflammatory activities\nin vivo and in vitro (Zhang and Li 2010). Based on these findings, the present study was undertaken to evaluate the protective effect of SeNPs against bleomycin-induced pulmonary injury in male rats in two early and late phases of the disease."
    }, {
      "heading" : "Materials and methods",
      "text" : ""
    }, {
      "heading" : "Ethics statement",
      "text" : "All experimental protocols were confirmed by the Ethical Committee of the Iran University of Medical Sciences. This study was conducted in accordance with the Helsinki Animal Ethics Committee guidelines for the use of experimental animals (Publications No. 85–23, revised in 1985)."
    }, {
      "heading" : "Animals",
      "text" : "Sixty healthy male albino Wistar rats (200–250 g, 8–10-wk-ofage) were used for the experiments. They were purchased from the Laboratory Animal Breeding Center of Iran University of Medical Sciences (Iran, Tehran). The rats were maintained in a controlled environment (temperature 22 C± 2 C, and humidity 50%) with 12/12 hours’ light/dark cycles. All rats had ad libitum access to filtered water and standard rodent chow. For the experiment, after a 2-week acclimatization period, rats were randomly allocated into six experimental groups (10/group) (Table 1)."
    }, {
      "heading" : "Characteristics of selenium nanoparticles",
      "text" : "The hydrodynamic size of the nanoparticles was measured by dynamic light scattering (DLS) (Malvern, Worcestershire, UK), and zeta potential was measured by Zeta Sizer (Malvern, Worcestershire, UK) according to the manufacturer’s instructions.\nTransmission electron microscopy (TEM) analysis\nBriefly, 10 ll of SeNPs was dropped onto carbon-coated copper grids and kept for drying. The dried sample was analyzed for size and morphology under the microscope at 200 kV. Then, the micrographs were obtained on TEM (Philips CM-10, FEI Inc., Hillsboro, Oregon, USA) as shown in Figure 1 (Kumar et al. 2014)."
    }, {
      "heading" : "ICP-MS analysis",
      "text" : "The analysis of SeNPs was based on the quantification of SeNPs in lung tissue using an inductively coupled plasmamass spectrometry (ICP-MS) method. Before analysis, lung tissue samples were thawed. About 40–60mg of each sample digested, and analyzed for SeNPs content. In brief, the tissue samples were digested in 5mL nitric acid (32% v/v) overnight. Then 1mL hydrogen peroxide (H2O2, 30% v/v, metal oxide semiconductor grade) was added to the solution. The solution ( 1mL) was diluted to a total volume of 2mL with 2% nitric acid. The detection limit of SeNPs was 0.001 ng/mL. Data are expressed as lg/g (parts per million, ppm) of tissue normalized to the control group. To determine the existing SeNPs in tissues, three rats were considered by each group. In the end, the measured SeNPs content in each group was normalized to the result of the control group."
    }, {
      "heading" : "Experimental protocols",
      "text" : "On day 0, rats were anesthetized with an intraperitoneal injection of a mixture of ketamine (100mg/kg) and xylazine (10mg/kg). The trachea was exposed after a small cervical skin incision. A tracheal cannula was entered into the trachea. Then, the pulmonary injury model was established by intratracheal instillation of bleomycin sulfate (Cell Pharm Gmbh, Hannover, Germany) solution in a single dose of 4mg/kg body weight, dissolved in 50 ml saline. Sham animals received saline without BLM. The cannula was then removed and the skin closed with surgical suture (Zaafan et al. 2016). In early phase group, one day after the treatment with BLM [or saline], rats received an IP injection of 0.5mg SeNP/kg for five consecutive days. Animals in late phase group, received an IP injection of 0.5mg SeNP/kg at day seven after treatment with BLM [or saline] and injection was repeated for five consecutive days (Hassanin et al. 2013). This particular dose of SeNPs was selected based on the study of Peng et al. (2007). SeNPs (size 23 nm) were purchased from the Iranian Nonmaterials Pioneers Company; NANOSANY (Mashhad, Iran).\nSample collection and analytical procedures\nOn day 21 after BLM instillation, the animals were deeply anesthetized with a mixture of ketamine (100mg/kg) and xylazine (10mg/kg), and blood samples were collected from the abdominal aorta, and then the rats were immediately sacrificed. The lungs were rapidly dissected out and washed with ice-cold saline. The right lung was preserved in 10% buffered formaldehyde for immunohistochemistry (IHC) and histopathologic examination. The left lung was frozen at 80 C for measurement of the TNF-a level. Each blood sample was centrifuged (10,000 g, 5min, 4 C), and the serum was isolated and stored at 80 C, until analysis of TNF-a level."
    }, {
      "heading" : "Histopathologic examination",
      "text" : "The right lung fixed for one week in 10% (w/v) buffered formaldehyde solution at room temperature; the tissue was dried in graded ethanol and fixed in paraffin. The paraffinembedded tissues were cut to 4-lm thicknesses with a microtome. Stained with hematoxylin and eosin (H&E) for evaluation of histopathological changes, and Masson’s trichrome staining was performed to identify the density of the accumulated collagen fibers. All slides were examined by a certified histologist (blinded manner) using an LX400 light microscope (LaboMed, Fremont, CA) at 400 magnifications. The degree of alveolitis and inflammation was reviewed by the method suggested by Szapiel et al. (1979) (Table 2). A total of 10 fields in each slide and 10 slides in each rat were examined. The mean score of all fields in each section was considered as the inflammatory score."
    }, {
      "heading" : "Immunohistochemistry",
      "text" : "For IHC, paraffin-embedded lung sections were deparaffinized by xylene three times, 10min each and subsequently rehydrated in graded alcohols (100%, 95%, 80%, and 70%) for 5min each. The blocking of the endogenous peroxidase was done in a dark place with incubating in 0.3% H2O2 at 37 C for 30min and then washed with phosphate buffered saline (PBS).\nAntigen retrieval was performed with citrate buffer (10mM citrate buffer, pH 6.0). The sections were heated in a microwave at 800W for 3min to initiate boiling of the solution and then for 7min at 400W to continue boiling. The sections were cooled for 30min at room temperature. After that, the 10-min heating procedure was repeated with fresh buffer and washed twice in PBS, 5min each. Then the\nslides were incubated for one hour with normal goat serum in PBS for blocking the unspecific binding sites. Then the sections were incubated with mouse anti-human monoclonal antibodies against TGF-b1 diluted 1:150 with PBS (Santa Cruz Biotechnology, (3C11): sc-130348 Dallas, TX), overnight at 4 C. After rinsing with PBS, the tissues were incubated with appropriate HRP-conjugated goat anti-mouse, (diluted 1:500 with PBS) for 30min at 37 C and washed twice in PBS, 5min each and visualized with diaminobenzidine (DAB) (Sigma, Saint Louise, Missouri, USA). Finally, the sections were counterstained using Hematoxylin and dehydrated using 95% and 100% alcohol and xylene. Positive stainingwas shown in a brown color, using an LX400 light microscope (LaboMed, Fremont, CA) at 40 magnifications."
    }, {
      "heading" : "Lung homogenate preparation",
      "text" : "One gram of the left lung (lower lobe) from each rat of the different groups was isolated and placed in PBS (100mg tissue per mL of homogenization buffer) (pH 7.4). The samples were then homogenized using a WiseTis HG-15D Homogenizer (Witeg Labortechnik GmbH, Wertheim, Germany), and then subjected to one round of freeze–thaw, and then sonicated using the T-18 Digital sonicator (T-18 Digital, IKA, Werke Staufen, Germany) for 10minutes, and then incubated at 4 C for 1 hour. The lung homogenates were centrifuged at 4000–6000 RPM, 4 C for 20min to remove insoluble debris. Then transfer the supernatant to a clean micro-centrifuge tube. The supernatants were used for assaying TNF-a level."
    }, {
      "heading" : "Enzyme-linked immunosorbent assay (ELISA)",
      "text" : "The level of tumor necrosis factor (TNF-a) in lung homogenate and in serum was determined using ELISA Kits (ZellBio, GmbH, Veltlinerweg, Germany), and the procedures were done matching to the manufacturer’s guidance. The level of sensitivity of the kits was 15 pg TNF-a/ml. All ELISAs were evaluated using a Synergy HT Multi-microplate reader (BioiTek, Winooski,\nVermont). According to the manufacturer’s instructions, 100 ll of the sample (serum and Lung homogenate) or diluted standard was poured in duplicate into wells. Then 50 ll of diluted biotinylated detection antibody was added and incubate 3 hours at room temperature. The wells were washed three times by washing buffer (distilled or deionized water). Then streptavidin-HRP (Horseradish Peroxidase) was added to all wells and then incubated 20min at room temperature. The wells were washed three times by washing buffer. 100 ll of ready-to-use TMB (Tetramethylbenzidine) was added to all wells. The wells incubated in the dark for 10–20minutes at room temperature for protection against direct exposure to light by wrapping the plate in aluminum foil. At the final step, 100 ll of H2SO4 (Stop Reagent) was added and immediately evaluated the absorbance value of each well on a Multi-microplate reader using 450 nm."
    }, {
      "heading" : "Statistical analysis",
      "text" : "All data were expressed as a mean± standard error of the mean. Statistical comparisons were made via one-way analysis of variance with Tukey’s post-hoc test. In all cases, a p value less than 0.05 was considered significant. All analyses were performed using SPSS version 21 (Sacramento, CA)."
    }, {
      "heading" : "Results",
      "text" : "Hydrodynamic size, surface charge, and characterization of selenium nanoparticles\nThe results of DLS showed that the hydrodynamic size of the nanoparticles was 25 ± 2 nm and the results of Zeta potential indicated that the surface charge was 29mV.\nLung tissue distribution of SeNPs\nLung tissue concentration of SeNPs 48 hours after the last injection SeNPs is shown in Figure 2. The result showed that\nFigure 3. The effect of intraperitoneal injection of SeNPs on the histological structure of the lung tissue after 21 days of bleomycin-induced pulmonary injury. Hematoxylin and eosin staining (H&E) (A): The control group shows the normal structure of the lung tissue. While the lung tissue sections of bleomycin-group show a thickening in alveolar septa, the collapse of alveolar spaces, loss of alveolar structure, obvious inflammatory cells infiltration, the proliferation of fibroblasts, and extracellular matrix deposition. Masson’s trichrome (B): An increase in interstitial collagen deposition in the BLM group was shown in comparison with the control group. Administration of SNPs in the early phase improves tissue changes induced by BLM injection. Viewed at a magnification of 400.\nFigure 4. The effect of intraperitoneal administration of SeNPs on the degree of alveolitis and inflammation. Data are expressed as means ± SEM (n¼ 10). The degree of alveolitis and inflammation are significantly decrease following intraperitoneal administration of SeNPs in animals treated in the early phase compared to BLM group damaged animals. p< 0.01 versus control group; #p< 0.05 versus BLM group.\nSeNPs appears in lung tissue after IP injection of the particle in SeNPs group, BLMþ SeNPs (early phase) group, and BLMþ SeNPs (late phase) group. The level of SeNPs in the other groups which did not receive an injection of the particle was zero."
    }, {
      "heading" : "Histopathologic analysis",
      "text" : "In this study, histological analysis was performed using H & E and Masson’s trichrome staining (Figure 3). The control group demonstrated the normal histological structure of the lung tissue such as thin interalveolar septa, intact alveolar structure, and normal alveolar septum. While the lung tissue sections of bleomycin-group showed that markedly histopathological abnormalities, including, thickening in alveolar septa, the collapse of alveolar spaces, loss of alveolar structure, obvious inflammatory cells infiltration, the proliferation of fibroblasts and extracellular matrix deposition. In contrast, administration of SeNPs in early phase leads to improved infiltration of inflammatory cells, the proliferation of fibroblasts, extracellular matrix deposition, and alveolar septal thickens. Moreover, Masson staining showed that the interstitial collagen deposition, which indicated with the blue color, was increased in the BLM group compare to the control group. Administration of SeNPs in early phase reduces interstitial collagen deposition (Figure 3). No sign of collagen deposition was observed with Masson’s trichrome staining in control group, SeNPs group, and sham group. Histopathological manifestations of the late phase group were similar to the BLM group (Figure 3). Similar results were observed in the degree of alveolitis and inflammation in Szapiel scoring (df: 5; F¼ 17.17; p< 0.001) (Figure 4). Administration of BLM resulted in a significant increase in the degree of alveolitis and inflammation as compared with the control rats (p< 0.001). The administration of SeNPs in early phase\nled to a significant decrease in the degree of alveolitis and inflammation when compared to animals received only BLM (p¼ 0.044). While administration of SeNPs in late phase had no effect on the degree of alveolitis and inflammation (p¼ 0.99). There were no significant differences between the control, sham and SeNPs groups (Figure 4)."
    }, {
      "heading" : "Immunohistochemical analyses",
      "text" : "After induction of pulmonary injury by BLM, TGF-b1 immunostaining showed the different distribution of this cytokine in different regions of the lung. In the lungs of the BLM group, alveoli, neutrophils, macrophages, endothelial cells, parenchymal cells, fibroblasts, and myofibroblasts show a significant increase in the distribution of TGF-b1 cytokine compared to the control group. While administration of SeNPs in early phase caused a significant decrease in density of TGFb1 in the lung compared with BLM group. In contrast, the injection of SeNPs in late phase had no effect on the reduction of TGF-b1 cytokine distribution compared to the control group (Figure 5). There were no significant differences between score values among the control, sham, and SeNPonly rats.\nTumor necrosis factor alpha level in serum\nThe statistical analyzes showed changes in TNF-a level in the serum at day 21 after bleomycin injection (df: 5; F¼ 37.83; p< 0.001) (Figure 6). In other words, administration of BLM leads to significantly increased the level of TNF-a in the serum compared to the control group (p< 0.001). While administration of SeNPs in early phase caused a significant decrease in the level of TNF-a in the serum compared to the BLM group (p< 0.001) and its level reached the control group level (p¼ 0.12). In contrast, administration of SeNPs in\nFigure 5. IHC of TGF-b1: The effect of intraperitoneal administration of SeNPs on the density of TGF-b1 in BLM-induced pulmonary injury. Viewed at a magnification of 40.\nlate phase did not show any change in the TNF-a level in the serum compared to the BLM group (p¼ 0.92) (Figure 6). In no cases were there significant differences between score values among the control, sham, and SeNP-only rats.\nTumor necrosis factor alpha level in lung homogenates\nAdministration of BLM resulted in changes in the tissue level of TNF-a in the studied groups after 21 days (df: 6; F¼ 14.21; p< 0.001) (Figure 7). TNF-a level of lung homogenates was significantly increased in the BLM group compared to the control group (p< 0.001). While the rats received SeNPs in early phase showed a significant decrease in the TNF-a level in the lung homogenates (p¼ 0.017) and its level reached the control group level (p¼ 0.062). There were no significant differences in TNF-a level in lung homogenates between the\nBLM group and late phase group (p¼ 0.087) (Figure 7). No significant differences were observed between control, sham groups and the group which received just SeNPs."
    }, {
      "heading" : "Discussion",
      "text" : "The current study evaluated the effects of administration of SeNPs as an anti-inflammatory agent and its potential protective function against BLM-induced pulmonary injury in rats. The results showed that administration of SeNPs during the early phase decreased serum and lung levels of TNF-a, and decreased the level of TGF-b1 in the lung. The data also showed that administration of SeNPs in early phase relieves BLM-induce inflammation and alveolitis, as well as histologic markers of the damage. While administration of SeNPs in the late phase did not impart any beneficial effects.\nFigure 6. The effect of intraperitoneal administration of SeNPs on TNF-a level in the serum. Data are expressed as means ± SEM (n¼ 10 in each group). TNF-a level in the serum are significantly decrease following intraperitoneal administration of SeNPs in animals treated in the early phase compared to BLM group damaged animals. p< 0.01 versus control group; #p< 0.01 versus BLM group.\nFigure 7. The effect of intraperitoneal administration of SeNPs on TNF-a level in the lung homogenates. Data are expressed as means ± SEM (n¼ 10 in each group). TNF-a level in the lung homogenates is significantly decreased following intraperitoneal administration of SeNPs in animals treated in the early phase compared to BLM group damaged animals. p< 0.01 versus control group; #p< 0.05 versus BLM group; p< 0.05 versus control group.\nTGF-b1 is a cytokine that plays a major role in the initiation, progression, and expansion of pulmonary fibrosis (Bonniaud et al. 2005). Increased level of TGF- b1 directly lead to the transformation of fibroblasts to myofibroblasts and stimulate the secretion of collagen by lung fibroblasts (Liu et al. 2017). Reportedly, increase expression of TGF-b1 using adenovirus-mediated gene transfer to rat lung induces severe and advanced pulmonary fibrosis (Sime et al. 1997).\nTNF-a has inflammatory and fibrogenic properties. A high level of TNF-a in surgical biopsies and serum samples from patients with idiopathic pulmonary fibrosis have been shown. Increasing the expression of this cytokine in the lung of the mice causes the expansion of progressive pulmonary fibrosis. After injection of bleomycin, TNF-a is produced by macrophages and many other types of cells in the lung. Overexpression of TNF-a results in an increase of fibroblasts and extracellular matrix deposition in the pulmonary interstitium (Wynn 2011, Della Latta et al. 2015). The results of this study indicated that BLM administration led to increased levels of TNF-a in the serum and lung tissues as well as increases TGF-b1 levels in different areas of the lung.\nIt is well-known that instillation of BLM is capable to create the different phases of pulmonary inflammation, and fibrogenesis (Smith et al. 1995). The intratracheal injection of bleomycin in animals immediately leads to the secretion of proinflammatory cytokines like as TNF-a, interleukin-6, interleukin-1, interferon-c as well as increases the expression of pro-fibrotic factors such as transforming growth factor-b1, fibronectin, procollagen-1 (Chaudhary et al. 2006). These changes have been reported in lung tissues. We also measured the changes of TNF-a in serum. As mentioned, the distribution of TGF-b in lung tissue was significantly increased in BLM injected animals. Also, the increased level of TNF-a was obvious in lung tissue and serum. SeNPS have high biological activities and low toxicity than selenium itself (Zhang et al. 2001). Several studies have shown that SeNPs imparted anti-inflammatory activity in vivo and in vitro (Zhang and Li 2010, El-Ghazaly et al. 2017). Results from our studies confirm these results. The anti-inflammatory effects of SeNPs were more readily to occur during an early phase. We showed that administration of SeNPs in BLM injected animals is able to release the inflammation by decreasing the level of TNF-a and TGF-b.\nThese data were similar to those in previous studies (Zaafan et al. 2016, El-Ghazaly et al. 2017) which demonstrated that SeNPs were capable of significantly reducing the TNF-a level and attenuating the infiltration of monocytes, granulocytes, and leukocytes and alleviate/reduce inflammation induced by irradiation in experimental animals. In this study, administration of SeNPs during the early phase of BLM-induced pulmonary injury seemed to relieve the destructive effects of BLM on TNF-a level and production of TGF-b in different areas of the lung. Likely, these are related to antiinflammatory effects of the SeNPs (Zhang and Li 2010, Mohammed and Safwat 2013).\nSuch anti-inflammatory effects have also been demonstrated in mice with gastrointestinal problems. It has been shown that the SeNPs caused decreases in TNF-a and IL-1b\nlevels in chemically-induced colitis in rats (Miroliaee et al. 2011).\nYu et al. (2017) showed that a significant improvement in lung fibrosis scores, TGF-b1, TNF-a, and platelet-derived growth factor (PDGF) levels in BLM-injected rats’ treated with, anti-inflammatory and antioxidant agent when given 1–2 days after administration of BLM. Huang et al. (2017) also reported that TNF-a and IL-1b levels and the number of inflammatory cells in bronchoalveolar lavage (BAL) fluid and expression of TGF-b1 in lung tissue were improved following subcutaneous administration of Kallistatin, one day after injection of BLM.\nZaafan et al. (2016) reported that administration of pyrrolidine dithiocarbamate (PDTC) as an antioxidant compound inhibits inflammatory cytokines when injected one week before BLM administration. Pyrrolidine dithiocarbamate caused a significant decrease in TGF-b1 and TNF-a levels in lung and reversed histological damages induced by BLM administration. The authors in the above studies suggested that their test agents might have protective and therapeutic effects against BLM-induced lung fibrosis. The present data showed that SeNPs were only effective when injected during the early phase (i.e., could improve [reduce] degree of inflammation and alveolitis, cause a decrease in TNF-a levels and TGF-b1 production in different areas of the lung) but did not show any protective effects when administrated during the late phase.\nIn another study, Mohammed and Safwat (2013) reported that SeNPs in two different sizes, (3–5 nm and 10–20 nm), imparted anti-inflammatory effects and could decrease the TNF-a level caused by paracetamol in kidney and brain tissue. Reportedly, SeNPs can significantly improve the inflammatory parameters, such as the C-reactive protein (CRP) and TNF-a in lung in cancer model (Ali et al. 2013).\nIt seems that one mechanism through which SeNPs could limits pulmonary injury is probably due to the anti-inflammatory effects of this compound and its potency to decrease the inflammatory cytokines such as TGF-b1 and TNF-a. However, with the advancement of the disease and the initiation of the fibrotic reactions (i.e., the proliferation of fibroblasts. collagen deposition), treatment with SeNPs was not effective. It would appear that anti-fibrotic compounds would be needed for treatment at this phase of the disease. The present study was the first in vivo study to investigate the protective effects of SeNPs on the recovery of inflammatory cytokines following induction of pulmonary injury."
    }, {
      "heading" : "Conclusion",
      "text" : "The results of the current study have shown that SeNPs have the protective and anti-inflammatory effects against bleomycin-induced pulmonary injury in rats when administered during the early phase of pulmonary injury. Administration of SeNPs on early phase was accompanied by significant reductions in TNF-a levels and also the production of TGF-b in different areas of the lung. Based on the findings, SeNPs may be a promising new therapeutic agent for potential use in early stages of pulmonary injury leading to PF. More\ninformation and experimental procedures are required for confirmation of the protective effect of SeNPs in the treatment of pulmonary fibrosis."
    }, {
      "heading" : "Disclosure statement",
      "text" : "No Potential conflict of interest was reported by the authors."
    }, {
      "heading" : "Funding",
      "text" : "This work was financially supported by Iran University of Medical Sciences, Tehran, Iran."
    } ],
    "references" : [ {
      "title" : "Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial",
      "author" : [ "C Albera" ],
      "venue" : null,
      "citeRegEx" : "Albera,? \\Q2009\\E",
      "shortCiteRegEx" : "Albera",
      "year" : 2009
    }, {
      "title" : "Evaluation of selenium nanoparticles as a potential chemopreventive agent against lung carcinoma",
      "author" : [ "E. Ali", "S. El-Sonbaty", "F. Salem" ],
      "venue" : "International Journal of Pharmacy and Biological Sciences,",
      "citeRegEx" : "Ali et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Ali et al\\.",
      "year" : 2013
    }, {
      "title" : "Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo",
      "author" : [ "T Arai" ],
      "venue" : "American Journal of Physiology-Lung Cellular and Molecular Physiology,",
      "citeRegEx" : "Arai,? \\Q2000\\E",
      "shortCiteRegEx" : "Arai",
      "year" : 2000
    }, {
      "title" : "Progressive transforming growth factor b1–induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor",
      "author" : [ "P Bonniaud" ],
      "venue" : "American Journal of Respiratory and Critical Care Medicine,",
      "citeRegEx" : "Bonniaud,? \\Q2005\\E",
      "shortCiteRegEx" : "Bonniaud",
      "year" : 2005
    }, {
      "title" : "Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model",
      "author" : [ "N.I. Chaudhary", "A. Schnapp", "J.E. Park" ],
      "venue" : "American Journal of Respiratory and Critical Care Medicine,",
      "citeRegEx" : "Chaudhary et al\\.,? \\Q2006\\E",
      "shortCiteRegEx" : "Chaudhary et al\\.",
      "year" : 2006
    }, {
      "title" : "Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions",
      "author" : [ "V Della Latta" ],
      "venue" : "Pharmacological Research,",
      "citeRegEx" : "Latta,? \\Q2015\\E",
      "shortCiteRegEx" : "Latta",
      "year" : 2015
    }, {
      "title" : "Selenium and inflammation: underlying antiinflammatory mechanisms",
      "author" : [ "L. Duntas" ],
      "venue" : "Hormone and Metabolic Research,",
      "citeRegEx" : "Duntas,? \\Q2009\\E",
      "shortCiteRegEx" : "Duntas",
      "year" : 2009
    }, {
      "title" : "Anti-inflammatory effect of selenium nanoparticles on the inflammation induced in irradiated rats",
      "author" : [ "El-Ghazaly", "M.A" ],
      "venue" : "Canadian Journal of Physiology and Pharmacology,",
      "citeRegEx" : "El.Ghazaly and M.A,? \\Q2017\\E",
      "shortCiteRegEx" : "El.Ghazaly and M.A",
      "year" : 2017
    }, {
      "title" : "Selenium in human health and disease",
      "author" : [ "Fairweather-Tait", "S.J" ],
      "venue" : "Antioxidants  Redox Signaling ,",
      "citeRegEx" : "Fairweather.Tait and S.J,? \\Q2011\\E",
      "shortCiteRegEx" : "Fairweather.Tait and S.J",
      "year" : 2011
    }, {
      "title" : "The prospective protective effect of selenium nanoparticles against chromium-induced oxidative and cellular damage in rat thyroid",
      "author" : [ "K.M. Hassanin", "S.H.A. El-Kawi", "K.S. Hashem" ],
      "venue" : "International Journal of Nanomedicine,",
      "citeRegEx" : "Hassanin et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Hassanin et al\\.",
      "year" : 2013
    }, {
      "title" : "The requirement and toxicity of selenium in rainbow trout (Salmo gairdneri)",
      "author" : [ "J. Hilton", "P. Hodson", "S. Slinger" ],
      "venue" : "The Journal of Nutrition,",
      "citeRegEx" : "Hilton et al\\.,? \\Q1980\\E",
      "shortCiteRegEx" : "Hilton et al\\.",
      "year" : 1980
    }, {
      "title" : "Kallistatin protects against bleomycin-induced idiopathic pulmonary fibrosis by inhibiting angiogenesis and inflammation",
      "author" : [ "X Huang" ],
      "venue" : "American Journal of Translational Research,",
      "citeRegEx" : "Huang,? \\Q2017\\E",
      "shortCiteRegEx" : "Huang",
      "year" : 2017
    }, {
      "title" : "The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities",
      "author" : [ "Z. Huang", "A.H. Rose", "P.R. Hoffmann" ],
      "venue" : "Redox",
      "citeRegEx" : "Huang et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Huang et al\\.",
      "year" : 2012
    }, {
      "title" : "Melatonin and selenium reduce plasma cytokine and brain oxidative stress levels in diabetic rats",
      "author" : [ "B. g" ],
      "venue" : "Brain Injury,",
      "citeRegEx" : "g,? \\Q2015\\E",
      "shortCiteRegEx" : "g",
      "year" : 2015
    }, {
      "title" : "Effect of glycosides based standardized fenu",
      "author" : [ "Kandhare", "A.D" ],
      "venue" : null,
      "citeRegEx" : "Kandhare and A.D,? \\Q2015\\E",
      "shortCiteRegEx" : "Kandhare and A.D",
      "year" : 2015
    }, {
      "title" : "Assessment of the ameliorative role",
      "author" : [ "E. Mohammed", "G. Safwat" ],
      "venue" : null,
      "citeRegEx" : "Mohammed and Safwat,? \\Q2013\\E",
      "shortCiteRegEx" : "Mohammed and Safwat",
      "year" : 2013
    }, {
      "title" : "Murine models of pulmonary",
      "author" : [ "B.B. Moore", "C.M. Hogaboam" ],
      "venue" : null,
      "citeRegEx" : "Moore and Hogaboam,? \\Q2008\\E",
      "shortCiteRegEx" : "Moore and Hogaboam",
      "year" : 2008
    }, {
      "title" : "Bleomycin-induced lung injury",
      "author" : [ "T Reinert" ],
      "venue" : "Journal of Cancer",
      "citeRegEx" : "Reinert,? \\Q2013\\E",
      "shortCiteRegEx" : "Reinert",
      "year" : 2013
    }, {
      "title" : "Biological effects of a nano red elemental selen",
      "author" : [ "Zhang", "J.-S" ],
      "venue" : null,
      "citeRegEx" : "Zhang and J..S,? \\Q2001\\E",
      "shortCiteRegEx" : "Zhang and J..S",
      "year" : 2001
    } ],
    "referenceMentions" : [ {
      "referenceID" : 12,
      "context" : "Selenium (Se) is an important micronutrient element, which is important for the prevention of neurodegeneration diseases and cancer (Huang et al. 2012).",
      "startOffset" : 132,
      "endOffset" : 151
    }, {
      "referenceID" : 10,
      "context" : "The limiting factors for using selenium are its bioavailability and toxicity; as it displays a narrow margin between effective and toxic doses (Hilton et al. 1980).",
      "startOffset" : 143,
      "endOffset" : 163
    }, {
      "referenceID" : 9,
      "context" : "5mg SeNP/kg at day seven after treatment with BLM [or saline] and injection was repeated for five consecutive days (Hassanin et al. 2013).",
      "startOffset" : 115,
      "endOffset" : 137
    }, {
      "referenceID" : 4,
      "context" : "The intratracheal injection of bleomycin in animals immediately leads to the secretion of proinflammatory cytokines like as TNF-a, interleukin-6, interleukin-1, interferon-c as well as increases the expression of pro-fibrotic factors such as transforming growth factor-b1, fibronectin, procollagen-1 (Chaudhary et al. 2006).",
      "startOffset" : 300,
      "endOffset" : 323
    }, {
      "referenceID" : 1,
      "context" : "Reportedly, SeNPs can significantly improve the inflammatory parameters, such as the C-reactive protein (CRP) and TNF-a in lung in cancer model (Ali et al. 2013).",
      "startOffset" : 144,
      "endOffset" : 161
    } ],
    "year" : 2019,
    "abstractText" : "Pulmonary fibrosis (PF) is an interstitial lung disease, in which the exact pathologic mechanisms are not fully understood. Drug trials for the treatment of PF have shown disappointing results and controversial. Recently, selenium nanoparticles (SeNPs) have received great attention for potential use in treatments, due to high bioactivity features and lower toxicity. This study evaluated the protective effect of SeNPs against pulmonary injury induced by bleomycin (single dose, 4mg/kg, intratracheal) in male rats in early and late phases of the disease. The rats were treated with SeNPs by intraperitoneal injection (0.5mg SeNP/kg) for five consecutive days in the early phase (a day after injection of bleomycin) and late phase (a week after injection of bleomycin). The results showed that injection of SeNPs in the early phase improved the degree of alveolitis and inflammation and lung structure damage. Also, led to significant decreases in density of transforming growth factorb1 (TGF-b1) in the lung and tumor necrosis factor-a (TNF-a) levels in the serum and lung homogenates compared with bleomycin-administrated group. Notably, treatment with the SeNP during the late phase did not show any ameliorative effects. Thus, the data suggest that SeNP has a protective effect against bleomycin-induced pulmonary injury in rats in the early phase of the disease. This might mean that SeNPs may be a new therapeutic agent for the improvement of this disease in the early phases. GRAPHICAL ABSTRACT ARTICLE HISTORY Received 30 June 2018 Revised 14 November 2018 Accepted 2 December 2018",
    "creator" : null
  }
}